Skip to main content
Gencurix Inc. logo

Gencurix Inc. — Investor Relations & Filings

Ticker · 229000 ISIN · KR7229000005 KO Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2025-08-28 Declaration of Voting R…
Country KR South Korea
Listing KO 229000

About Gencurix Inc.

https://www.gencurix.com/eng/

Gencurix Inc. is a molecular diagnostics company that develops and commercializes diagnostic solutions for precision medicine. The company's portfolio focuses primarily on oncology, offering prognostic, companion, and early detection tests. Key products include GenesWell BCT, a multigene prognostic test for early-stage breast cancer, and the GenesWell ddEGFR Mutation Test, a ddPCR-based companion diagnostic. Gencurix also utilizes its Droplex liquid biopsy platform for early cancer detection and develops diagnostic tests for infectious diseases. The company's core technologies include digital droplet PCR (ddPCR), real-time PCR, and liquid biopsy for analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Recent filings

Filing Released Lang Actions
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of an Extraordinary General Meeting (EGM) held on 2025-08-28. It details the voting outcomes for the appointment of directors and the granting of stock options. According to the filing definitions, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the correct category for official results from shareholder votes at any general meeting.
2025-08-28 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to directors and employees, including exercise prices, vesting periods, and valuation methods. This type of corporate action regarding capital structure and equity-based compensation is classified under 'Regulatory Filings' (RNS) as it is a specific statutory disclosure required by Korean financial regulations that does not fit into the other specialized categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for actual capital changes).
2025-08-28 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors) submitted to the Financial Services Commission/Korea Exchange. This document specifically details changes to the company's board of directors, specifically the appointment of an outside director. According to the provided definitions, announcements regarding changes in the board of directors or senior management fall under the 'MANG' category.
2025-08-28 Korean
[기재정정]주주총회소집결의 (임시주주총회)
AGM Information Classification · 98% confidence The document is a formal regulatory filing from Gencurix regarding the 'Resolution to Convene a General Meeting of Shareholders' (specifically an Extraordinary General Meeting). It details the date, time, location, and agenda items (such as the appointment of directors and stock option grants) for the upcoming meeting. This type of document is a standard proxy solicitation/information statement provided to shareholders to inform them of meeting details and agenda items, which falls under the Proxy Solicitation & Information Statement (PSI) category.
2025-08-13 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' (임시주주총회소집공고) for Gencurix, Inc. It details the meeting date, location, agenda items (appointment of directors, stock option grants), and provides management reference materials (경영참고사항) including director candidate profiles and business overviews. This document is a standard proxy statement/information circular provided to shareholders to solicit votes for an upcoming meeting.
2025-08-13 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for upcoming general meetings. It contains details about the meeting agenda, director candidates, and stock option grants. This falls under the 'Proxy Solicitation & Information Statement' category.
2025-08-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.